Business
Currency:USD
2024/Q1
Stock NameRevenueRatio
Coronavirus disease 2019 (COVID-19)23.13M42.73%
Human immunodeficiency virus (HIV)13.38M24.72%
Molecular Sample Management Solutions10.82M19.99%
Hepatitis C virus (HCV)3M5.54%
Risk assessment testing2.08M3.84%
Molecular Services873K1.61%
Other product and service revenues496K0.92%
Non-product and services revenues353K0.65%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
United States361.66M89.19%
Other regions35.7M8.80%
Europe8.11M2.00%
